The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

Uninsured Rate Climbs, Reviving Pre-ACA Coverage Fears

The share of working-age U.S. adults without health insurance is climbing, and it is doing so before the bigger coverage losses that analysts expect in 2026. That has some healthcare leaders invoking the pre-Affordable Care Act era, when more Americans went without coverage and leaned on emergency departments for care they could not get elsewhere, according to Becker's Hospital Review.

The warning draws on the Commonwealth Fund's Biennial Health Insurance Survey, a long-running gauge of coverage trends. The concern is directional as much as numerical: the rate is backsliding now, and additional policy changes threaten to accelerate the decline next year.

For hospitals and health systems, rising uninsurance translates into more uncompensated care, higher reliance on emergency settings, and pressure on already thin margins. For patients, losing coverage often means delaying care until conditions worsen. The practical takeaway for operators is to prepare for a payer mix shift and a possible return to dynamics the ACA was designed to reduce.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.